Francesco Franchi, M.B.Ch.B. (M.D.)

Francesco Franchi M.B.Ch.B. (M.D.)

Assistant Professor

Department: Department of Medicine
Business Phone: (904) 244-2060

Clinical Profile

Specialties
  • Cardiovascular Disease
Languages
  • Speaks English and Italian

Publications

2023
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor
JACC: Cardiovascular Interventions.16(1):36-46[DOI] 10.1016/j.jcin.2022.10.034.[PMID] .
2022
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
European heart journal.43(10):959-967[DOI] 10.1093/eurheartj/ehab836.[PMID] 34918066.
2022
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Journal of the American Heart Association.11(4):e024159-[DOI] 10.1161/JAHA.121.024159.[PMID] 35156424.
2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.
2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease
Journal of Thrombosis and Thrombolysis.54(3):461-469[DOI] 10.1007/s11239-022-02696-4.[PMID] .
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics.112(1):146-155[DOI] 10.1002/cpt.2612.[PMID] 35429163.
2022
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.
Nature reviews. Cardiology.19(12):829-844[DOI] 10.1038/s41569-022-00725-6.[PMID] 35697777.
2022
Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.15(8):807-809[DOI] 10.1016/j.jcin.2022.02.048.[PMID] 35450680.
2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.
2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.
2022
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
JACC. Cardiovascular interventions.15(2):230-231[DOI] 10.1016/j.jcin.2021.12.002.[PMID] 35057998.
2022
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
European heart journal. Cardiovascular pharmacotherapy.8(7):677-686[DOI] 10.1093/ehjcvp/pvab070.[PMID] 34519777.
2021
Dual pathway inhibition in atherothrombosis prevention: yes, now we can!
Minerva cardiology and angiology.():-[DOI] 10.23736/S2724-5683.21.05867-1.[PMID] 34761666.
2021
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study
BMJ Open Diabetes Research & Care.9(1):e001939-[DOI] 10.1136/bmjdrc-2020-001939.[PMID] 33637605.
2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
Expert review of clinical pharmacology.14(8):963-978[DOI] 10.1080/17512433.2021.1927709.[PMID] 33993817.
2021
Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease.
JACC. Cardiovascular interventions.14(7):751-753[DOI] 10.1016/j.jcin.2021.02.005.[PMID] 33744206.
2021
Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization.
International journal of cardiology.345():36-38[DOI] 10.1016/j.ijcard.2021.10.010.[PMID] 34678324.
2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Lancet (London, England).397(10283):1470-1483[DOI] 10.1016/S0140-6736(21)00533-X.[PMID] 33865495.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.109(3):705-715[DOI] 10.1002/cpt.2039.[PMID] 32897581.
2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.
2021
Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.
Trends in cardiovascular medicine.():-[DOI] 10.1016/j.tcm.2021.12.007.[PMID] 34936903.
2021
Typical atrial flutter from blunt cardiac injury: an atypical cause.
Journal of geriatric cardiology : JGC.18(2):155-157[DOI] 10.11909/j.issn.1671-5411.2021.02.009.[PMID] 33747066.
2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
Journal of Thrombosis and Thrombolysis.51(3):741-747[DOI] 10.1007/s11239-021-02386-7.[PMID] 33582955.
2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
Clinical and translational science.13(3):473-481[DOI] 10.1111/cts.12729.[PMID] 31758664.
2020
Clopidogrel drug interactions: a review of the evidence and clinical implications.
Expert opinion on drug metabolism & toxicology.16(11):1079-1096[DOI] 10.1080/17425255.2020.1814254.[PMID] 32835535.
2020
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics.22(11):1919-[DOI] 10.1038/s41436-020-0931-1.[PMID] 32747766.
2020
Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network.
Pharmacogenomics and personalized medicine.13():217-226[DOI] 10.2147/PGPM.S241599.[PMID] 32765043.
2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.
2020
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics.22(11):1898-1902[DOI] 10.1038/s41436-020-0894-2.[PMID] 32678355.
2020
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.
2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.
2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.
2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.
Journal of the American Heart Association.8(6):e011139-[DOI] 10.1161/JAHA.118.011139.[PMID] 30857464.
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.
2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.
2019
Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations.
Therapeutic advances in hematology.10():2040620719861475-[DOI] 10.1177/2040620719861475.[PMID] 31321012.
2019
Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.12(23):2342-2345[DOI] 10.1016/j.jcin.2019.10.017.[PMID] 31806215.
2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.12(16):1521-1537[DOI] 10.1016/j.jcin.2019.03.034.[PMID] 31202949.
2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Nature reviews. Cardiology.15(8):480-496[DOI] 10.1038/s41569-018-0049-1.[PMID] 29973709.
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine.16(1):92-[DOI] 10.1186/s12967-018-1469-8.[PMID] 29642909.
2018
Diabetes and antiplatelet therapy: from bench to bedside.
Cardiovascular diagnosis and therapy.8(5):594-609[DOI] 10.21037/cdt.2018.05.09.[PMID] 30498684.
2018
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.
Progress in cardiovascular diseases.60(4-5):478-490[DOI] 10.1016/j.pcad.2017.12.004.[PMID] 29291426.
2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical pharmacology and therapeutics.104(4):664-674[DOI] 10.1002/cpt.1006.[PMID] 29280137.
2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.
2018
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Journal of cardiovascular pharmacology and therapeutics.23(1):23-37[DOI] 10.1177/1074248417708617.[PMID] 28565918.
2018
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Expert review of clinical pharmacology.11(2):151-164[DOI] 10.1080/17512433.2017.1353909.[PMID] 28689434.
2018
Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention: Finding the Balance for Patients With Stable Coronary Artery Disease.
Circulation.138(13):1301-1303[DOI] 10.1161/CIRCULATIONAHA.118.036240.[PMID] 30354428.
2018
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Expert review of hematology.11(1):5-12[DOI] 10.1080/17474086.2018.1400378.[PMID] 29091481.
2018
The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI.
Journal of the American College of Cardiology.71(11):1243-1245[DOI] 10.1016/j.jacc.2018.01.040.[PMID] 29544608.
2017
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
Nature reviews. Cardiology.14(6):361-379[DOI] 10.1038/nrcardio.2017.18.[PMID] 28230176.
2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Thrombosis and haemostasis.117(5):940-947[DOI] 10.1160/TH16-09-0703.[PMID] 28300867.
2017
Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.12(14):1681-1683[DOI] 10.4244/EIJV12I14A276.[PMID] 28216470.
2017
De-Escalation of Platelet P2Y12 Receptor Inhibiting Therapy After Percutaneous Coronary Intervention: Does One Size Fit All?
JACC. Cardiovascular interventions.10(24):2571-2573[DOI] 10.1016/j.jcin.2017.10.007.[PMID] 29268887.
2017
Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors: How Real Is It?
JACC. Cardiovascular interventions.10(2):130-132[DOI] 10.1016/j.jcin.2016.11.021.[PMID] 28104205.
2017
Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.
Thrombosis and haemostasis.117(1):201-203[DOI] 10.1160/TH16-08-0594.[PMID] 27786340.
2017
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Journal of the American Heart Association.6(4):-[DOI] 10.1161/JAHA.117.005650.[PMID] 28356282.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics.18(5):421-426[DOI] 10.2217/pgs-2017-0028.[PMID] 28346068.
2017
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.
Circulation.136(20):1955-1975[DOI] 10.1161/CIRCULATIONAHA.117.031164.[PMID] 29084738.
2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients.
JACC. Cardiovascular interventions.10(13):1374-1375[DOI] 10.1016/j.jcin.2017.04.027.[PMID] 28683943.
2017
Oral trans-mucosal administration of ticagrelor: is this really the future?
Thrombosis and haemostasis.117(5):826-828[DOI] 10.1160/TH17-03-0177.[PMID] 28331923.
2017
Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.69(2):250-251[DOI] 10.1016/j.jacc.2016.09.982.[PMID] 28081837.
2017
Switching from ticagrelor to clopidogrel: New answers and further questions.
Thrombosis and haemostasis.117(2):207-208[DOI] 10.1160/TH16-12-0909.[PMID] 28004060.
2017
Switching P2Y12 Receptor Inhibiting Therapies.
Interventional cardiology clinics.6(1):67-89[DOI] 10.1016/j.iccl.2016.08.006.[PMID] 27886824.
2017
The role of oral anticoagulant therapy in patients with acute coronary syndrome.
Therapeutic advances in hematology.8(12):353-366[DOI] 10.1177/2040620717733691.[PMID] 29204262.
2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
European heart journal.37(35):2722-30[DOI] 10.1093/eurheartj/ehv744.[PMID] 26848148.
2016
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Expert opinion on drug safety.15(2):275-85[DOI] 10.1517/14740338.2016.1133585.[PMID] 26680584.
2016
Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.
Circulation journal : official journal of the Japanese Circulation Society.80(4):791-801[DOI] 10.1253/circj.CJ-16-0208.[PMID] 26984587.
2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.
2016
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.9(3):228-230[DOI] 10.1016/j.jcin.2015.11.022.[PMID] 26777325.
2016
Dual antiplatelet therapy after coronary stenting.
Expert opinion on pharmacotherapy.17(13):1775-87[DOI] 10.1080/14656566.2016.1202924.[PMID] 27309035.
2016
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Thrombosis and haemostasis.115(3):622-31[DOI] 10.1160/TH15-06-0467.[PMID] 26633836.
2016
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Journal of the American College of Cardiology.67(6):603-613[DOI] 10.1016/j.jacc.2015.11.044.[PMID] 26868683.
2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.
Thrombosis and haemostasis.116(6):1060-1069[DOI] .[PMID] 27488362.
2016
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Circulation.134(11):780-92[DOI] 10.1161/CIRCULATIONAHA.116.023402.[PMID] 27559041.
2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.
2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Journal of the American College of Cardiology.67(10):1145-1154[DOI] 10.1016/j.jacc.2015.12.062.[PMID] 26965534.
2016
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Nature reviews. Cardiology.13(1):11-27[DOI] 10.1038/nrcardio.2015.113.[PMID] 26283269.
2016
The Conundrum of Platelet P2Y12 Inhibition in ST-Segment Elevation Myocardial Infarction.
Circulation journal : official journal of the Japanese Circulation Society.80(12):2429-2431[DOI] .[PMID] 27795489.
2016
The Paradox of Smoking and Clopidogrel Effect - Dr Jekyll or Mr Hyde?
Circulation journal : official journal of the Japanese Circulation Society.80(7):1529-31[DOI] 10.1253/circj.CJ-16-0508.[PMID] 27302849.
2016
Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.
Trends in cardiovascular medicine.26(4):321-34[DOI] 10.1016/j.tcm.2015.08.002.[PMID] 26391344.
2015
[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
Giornale italiano di cardiologia (2006).16(5):277-80[DOI] 10.1714/1870.20424.[PMID] 25994462.
2015
Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.
Circulation. Cardiovascular interventions.8(6):e002760-[DOI] 10.1161/CIRCINTERVENTIONS.115.002760.[PMID] 26056251.
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.
2015
Novel antiplatelet agents in acute coronary syndrome.
Nature reviews. Cardiology.12(1):30-47[DOI] 10.1038/nrcardio.2014.156.[PMID] 25286881.
2015
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
Progress in cardiovascular diseases.58(3):267-77[DOI] 10.1016/j.pcad.2015.08.009.[PMID] 26277706.
2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.
2015
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
Future cardiology.11(5):547-64[DOI] 10.2217/fca.15.50.[PMID] 26406386.
2015
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.
Journal of the American College of Cardiology.65(16):1714-1715[DOI] 10.1016/j.jacc.2014.12.069.[PMID] 25908082.
2015
Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.
Journal of thrombosis and thrombolysis.40(1):118-25[DOI] 10.1007/s11239-014-1130-1.[PMID] 25129122.
2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Journal of cardiovascular translational research.7(1):53-63[DOI] 10.1007/s12265-013-9535-3.[PMID] 24395495.
2014
Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis.37(3):358-[DOI] 10.1007/s11239-013-1003-z.[PMID] 24101257.
2014
Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.
Journal of cardiovascular translational research.7(1):47-52[DOI] 10.1007/s12265-013-9530-8.[PMID] 24357254.
2014
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Journal of the American College of Cardiology.64(10):1005-14[DOI] 10.1016/j.jacc.2014.06.1170.[PMID] 25190236.
2014
Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery.
Current opinion in cardiology.29(6):553-63[DOI] 10.1097/HCO.0000000000000104.[PMID] 25144343.
2014
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
JACC. Cardiovascular interventions.7(4):426-34[DOI] 10.1016/j.jcin.2013.11.019.[PMID] 24630878.
2014
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis.37(2):131-8[DOI] 10.1007/s11239-013-0979-8.[PMID] 23943337.
2014
Platelet function testing in contemporary clinical and interventional practice.
Current treatment options in cardiovascular medicine.16(5):300-[DOI] 10.1007/s11936-014-0300-y.[PMID] 24652579.
2014
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Vascular health and risk management.10():177-88[DOI] 10.2147/VHRM.S36045.[PMID] 24729713.
2013
Cangrelor: a review on pharmacology and clinical trial development.
Expert review of cardiovascular therapy.11(10):1279-91[DOI] 10.1586/14779072.2013.837701.[PMID] 24138516.
2013
Effect of cardiac resynchronization therapy on left atrial reverse remodeling: role of echocardiographic AV delay optimization.
International journal of cardiology.167(4):1456-60[DOI] 10.1016/j.ijcard.2012.04.046.[PMID] 22560916.
2013
Effects of Cangrelor in Prasugrel Treated Patients: a Pharmacodynamic in Vitro Investigation
Circulation.128(22, S):-[DOI] .[PMID] .
2013
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Thrombosis and haemostasis.110(4):777-84[DOI] 10.1160/TH13-05-0400.[PMID] 23884248.
2013
Indexed maximal left atrial volume predicts response to cardiac resynchronization therapy.
International journal of cardiology.168(4):3629-33[DOI] 10.1016/j.ijcard.2013.05.028.[PMID] 23725913.
2013
Pharmacodynamic Effects of Ev-077 in Patients With Diabetes Mellitus On Clopidogrel Monotherapy: Results of An in Vitro Pilot Investigation
Journal of the American College of Cardiology.61():E1830-[DOI] .[PMID] .
2013
Platelet function profiles in patients with diabetes mellitus.
Journal of cardiovascular translational research.6(3):329-45[DOI] 10.1007/s12265-013-9449-0.[PMID] 23404189.
2013
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
Therapeutic advances in cardiovascular disease.7(4):197-213[DOI] 10.1177/1753944713487781.[PMID] 23818658.

Office Information

Academic Office
5th Floor, Ambulatory Care Center
655 West 8th Street, C35
Jacksonville, FL 32209
(904) 244-2655
francesco.franchi@jax.ufl.edu
Medical Secretary
Monica George
(904) 244-2060
monica.george@jax.ufl.edu

Education

Medical Degree
2006 · University of Modena and Reggio Emilia, Modena, Italy
Cardiovascular Disease Fellowship
2011 · University of Modena and Reggio Emilia, Modena, Italy